stockrow
Friday 6 November 2026
Export EOLS’s income statement to Excel — free account
Evolus, Inc.
EOLS Healthcare Drug Manufacturers Specialty & Generic
Evolus, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $297.2 million, up 11.6% from fiscal 2024.
- Revenue
- +13.0%
- EPS
- +21.1%
- Free cash flow
- +77.7%
- Total debt
- +7.63%
Quarter to September 2026, against a year earlier
6.86
0.06
+0.88%
Follow EOLS
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.62 | 1.45 | 0.89 | 1.44 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(273.50) | (127.56) | (26.92) | 33.42 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.21 | 2.03 | 1.49 | 2.00 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(271.56) | (41.84) | (12.27) | (14.09) | |
EV/FCF |
(81.47) | (29.39) | (10.01) | (11.74) | |
Quick Ratio |
0.72 | 1.09 | 1.50 | 1.44 | |
Current Ratio |
1.42 | 1.70 | 2.04 | 1.90 | |
Net Debt/EBITDA |
(22.92) | (77.00) | (28.07) | 12.90 | |
Debt/Assets |
55.28% | 63.20% | 70.89% | 64.68% | |
Debt/Equity |
(4.15) | (5.07) | (5.43) | (6.32) | |
Asset Turnover |
1.29 | 1.33 | 1.39 | 1.30 | |
Operating CF/Net income |
0.15 | 0.45 | 0.93 | 98.67 | |
Capex/Depreciation |
(0.53) | (0.16) | (0.55) | (0.74) | |
Interest Coverage |
(1.98) | (1.09) | (1.72) | 1.06 | |
Research and Development Expense of Revenue |
2.52% | 2.25% | 3.06% | 3.85% | |
Selling, General and Administrative Expense of Revenue |
67.89% | 67.85% | 71.07% | 60.53% | |
Intangible Assets out of Total Assets |
0.24 | 0.27 | 0.31 | 0.31 | |
Share Based Compensation of Revenue |
7.19% | 6.69% | 7.00% | 5.70% | |
Graham Net Nets |
(0.23) | (0.24) | (0.41) | (0.25) | |
Graham Number |
2.46 | 2.34 | 2.58 | 2.56 | |
Earnings Yield |
(5.87%) | (7.49%) | (16.30%) | (12.18%) | |
Free Cash Flow Yield |
(1.67%) | (4.79%) | (16.75%) | (11.83%) | |
Revenue per Share |
1.18 | 1.28 | 1.12 | 1.40 | |
Operating CF per Share |
(0.03) | (0.05) | (0.15) | 0.20 | |
Capex per Share |
(0.03) | (0.01) | (0.03) | (0.03) | |
Free Cash Flow per Share |
(0.06) | (0.06) | (0.18) | 0.17 | |
Cash per Share |
0.63 | 0.69 | 0.76 | 0.83 | |
Shareholders Equity per Share |
(0.57) | (0.47) | (0.44) | (0.36) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.57) | (0.47) | (0.44) | (0.36) | |
Free Cash Flow |
(3.75) | (4.09) | (11.64) | 10.66 | |
Working Capital |
59.36 | 68.81 | 70.90 | 67.61 | |
Capital Expenditures |
(1.81) | (0.50) | (1.69) | (2.17) | |
Net Current Asset Value |
(119.90) | (111.38) | (110.50) | (106.06) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.01 | 0.02 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
55.36 | 55.05 | 49.84 | 51.19 | |
Average Payables |
54.57 | 33.90 | 17.85 | 16.30 | |
Average Inventory |
57.84 | 33.68 | 17.41 | 19.56 | |
Average Assets |
251.41 | 238.41 | 217.00 | 229.22 | |
Average Common Equity |
(33.29) | (24.78) | (17.69) | (8.79) |
Columns are period end dates · fundamentals updated 6 Nov 2026